Revance Therapeutics
Market Cap
US$832.5m
Last Updated
2019/12/13 00:45 UTC
Data Sources
Company Financials +
Executive Summary
Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Revance Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RVNC's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
0.9%
RVNC
2.1%
US Pharmaceuticals
1.3%
US Market
1 Year Return
-17.4%
RVNC
1.0%
US Pharmaceuticals
19.4%
US Market
Return vs Industry: RVNC underperformed the US Pharmaceuticals industry which returned 1% over the past year.
Return vs Market: RVNC underperformed the US Market which returned 19.4% over the past year.
Shareholder returns
| RVNC | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.9% | 2.1% | 1.3% |
| 30 Day | 9.2% | 6.9% | 2.6% |
| 90 Day | 26.8% | 9.2% | 5.0% |
| 1 Year | -17.4%-17.4% | 3.7%1.0% | 22.0%19.4% |
| 3 Year | -8.4%-8.4% | 30.4%21.0% | 46.8%37.3% |
| 5 Year | -6.8%-6.8% | 24.5%11.3% | 66.3%48.0% |
Price Volatility Vs. Market
How volatile is Revance Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
How Does Investing In Revance Therapeutics, Inc. (NASDAQ:RVNC) Impact The Volatility Of Your Portfolio?1 month ago | Simply Wall St
Imagine Owning Revance Therapeutics (NASDAQ:RVNC) And Wondering If The 41% Share Price Slide Is Justified2 months ago | Simply Wall St
Companies Like Revance Therapeutics (NASDAQ:RVNC) Are In A Position To Invest In GrowthValuation
Is Revance Therapeutics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RVNC ($16.45) is trading below our estimate of fair value ($254.39)
Significantly Below Fair Value: RVNC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RVNC is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: RVNC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RVNC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RVNC is overvalued based on its PB Ratio (4.8x) compared to the US Pharmaceuticals industry average (3.1x).
Next Steps
Future Growth
How is Revance Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
52.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RVNC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RVNC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RVNC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RVNC's revenue (74.6% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: RVNC's revenue (74.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RVNC's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Revance Therapeutics performed over the past 5 years?
-21.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RVNC is currently unprofitable.
Growing Profit Margin: RVNC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RVNC is unprofitable, and losses have increased over the past 5 years at a rate of -21.5% per year.
Accelerating Growth: Unable to compare RVNC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RVNC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.3%).
Return on Equity
High ROE: RVNC has a negative Return on Equity (-102.27%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Revance Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: RVNC's short term assets ($220.6M) exceed its short term liabilities ($34.2M).
Long Term Liabilities: RVNC's short term assets ($220.6M) exceed its long term liabilities ($80.4M).
Debt to Equity History and Analysis
Debt Level: RVNC is debt free.
Reducing Debt: RVNC has no debt compared to 5 years ago when its debt to equity ratio was 1%.
Balance Sheet
Inventory Level: RVNC has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if RVNC's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RVNC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RVNC has less than a year of cash runway if free cash flow continues to reduce at historical rates of -18.9% each year
Next Steps
Dividend
What is Revance Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate RVNC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RVNC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RVNC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RVNC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RVNC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Revance Therapeutics's salary, the management and board of directors tenure and is there insider trading?
1.6yrs
Average management tenure
CEO
Mark Foley (54yo)
0.2yrs
Tenure
US$243,007
Compensation
Mr. Mark J. Foley serves as President and Chief Executive Officer at Revance Therapeutics, Inc. since October 14, 2019. He served as the Managing Director of RWI Ventures from 2004 to 2018. Mr. Foley joine ...
Management Age and Tenure
1.6yrs
Average Tenure
49yo
Average Age
Experienced Management: RVNC's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Age and Tenure
4.1yrs
Average Tenure
61.5yo
Average Age
Experienced Board: RVNC's board of directors are considered experienced (4.1 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.6%.
Management Team
Mark Foley (54yo)
President
- Tenure: 0.2yrs
- Compensation: US$243.01k
Abhay Joshi (56yo)
Chief Operating Officer
- Tenure: 4yrs
- Compensation: US$2.25m
Jeanie Herbert
Senior Director of Investor Relations & Corporate Communications
- Tenure: 3yrs
Dustin Sjuts
Head of Commercial - Aesthetics & Therapeutics
- Tenure: 1.1yrs
Roman Rubio (48yo)
Senior Vice President of Clinical Development
- Tenure: 0yrs
Justin Ford
VP of Human Resources & Head of People
- Tenure: 2.5yrs
Caryn McDowell (49yo)
Senior VP
- Tenure: 1.6yrs
- Compensation: US$2.80m
Toby Schilke (44yo)
CFO & Principal Accounting Officer
- Tenure: 1.1yrs
- Compensation: US$1.97m
Conor Gallagher
Head of Medical Affairs & Aesthetics
- Tenure: 1.6yrs
Taryn Conway
Vice President of Marketing
- Tenure: 0.7yrs
Board Members
Angus Russell (63yo)
Independent Chairman
- Tenure: 5.8yrs
- Compensation: US$269.98k
Phyllis Gardner (68yo)
Independent Director
- Tenure: 13yrs
- Compensation: US$233.01k
Bob Byrnes (74yo)
Independent Director
- Tenure: 15.3yrs
- Compensation: US$247.26k
Mark Foley (54yo)
President
- Tenure: 0.2yrs
- Compensation: US$243.01k
Jill Beraud (59yo)
Director
- Tenure: 0.5yrs
Phil Vickers (59yo)
Independent Director
- Tenure: 4.8yrs
- Compensation: US$235.26k
Julian Gangolli (61yo)
Independent Director
- Tenure: 3.4yrs
- Compensation: US$230.51k
Chris Nolet (62yo)
Director
- Tenure: 0.4yrs
Company Information
Revance Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Revance Therapeutics, Inc.
- Ticker: RVNC
- Exchange: NasdaqGM
- Founded: 1999
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$832.508m
- Shares outstanding: 50.61m
- Website: https://www.revance.com
Number of Employees
Location
- Revance Therapeutics, Inc.
- 7555 Gateway Boulevard
- Newark
- California
- 94560
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| RVNC | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Feb 2014 |
| RTI | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2014 |
Biography
Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/13 00:45 |
| End of Day Share Price | 2019/12/12 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.